Q2 2026 Kyntra Bio, Inc. Earnings Call Transcript
Key Points
- FG-3246 Phase 2 interim analysis on track for Q4 2026, with potential to improve upon the 8.7-month median rPFS seen in Phase 1.
- FG-3246 demonstrated encouraging efficacy in heavily pre-treated mCRPC patients, including a 36% PSA50 response and 20% ORR with durable responses.
- Companion diagnostic FG-3180 shows early correlation between CD46 expression and response, supporting a biomarker-driven strategy.
- Roxadustat Phase 3 protocol finalized with FDA, targeting initiation in Q4 2026, and showing transfusion independence rates comparable to approved therapies.
- Cash runway into 2028 provides financial stability to advance key clinical milestones.
- Roxadustat has potential in RS-negative patients, a segment with high unmet need where current therapies are limited.
- Total revenue was negative $1.5 million in Q2 2026, a decline from $1.3 million in the prior year.
- Operating expenses increased to $16.1 million in Q2 2026 from $13.4 million in Q2 2025, driven by higher R&D and SG&A costs.
- Phase 3 roxadustat initiation is contingent on securing additional capital or a strategic partner, creating uncertainty.
- FG-3246 Phase 2 interim analysis may not meet futility criteria, and mature rPFS data will not be available until 2027.
- The company faces competitive pressure from PSMA-directed therapies like Pluvicto, which may limit FG-3246's market share.
- Potential economic dilution if partnering roxadustat, as AstraZeneca would receive 35% of any economics from a partnership.
Please be advised that todayâs conference is being recorded. I would now like to hand the conference over to your speaker today, Gaia Vasiliver-Shamis of LifeSci Advisors. Please go ahead.
Thank you, Latonia, and good afternoon, everyone. Thank you for joining today to discuss Kyntra Bioâs second quarter 2026 financial and business results. Iâm Gaia Shamis from LifeSci Advisors. Joining me on todayâs call are Thane Wettig, Chief Executive Officer; David DeLucia, Chief Financial Officer; and Carol Gaddum, Vice President of Product Development.
Following the prepared remarks, we will open the call to your questions. I would like to remind you that remarks made on todayâs call include forward-looking statements about Kyntra Bio. Such statements may include, but are not limited to, collaborations with AstraZeneca and Astellas, financial guidance, the initiation, enrollment, design, conduct, and results of clinical trials, regulatory strategies and potential regulatory results, research and development
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
